Mucus has been shown to tame microbes in new study
Posted: 15 October 2019 | Rachael Harper (Drug Target Review) | No comments yet
Glycans, which are found in mucus, have the ability to regulate how microbes behave and could lead to new therapeutics.


A new study from MIT, US has revealed that glycans – branched sugar molecules found in mucus – can prevent bacteria from communicating with each other and forming infectious biofilms, effectively rendering them harmless. The researchers suggest that mucus could have therapeutic applications.
“These glycans have biological functions that are very broad and sophisticated,” said Katharina Ribbeck, the Mark Hyman, Jr Career Development Professor of Biological Engineering at MIT. “They have the ability to regulate how microbes behave and really tune their identity.”
Ribbeck wanted to test whether glycans were involved in mucus’ ability to control the behaviour of microbes so she isolated glycans and exposed them to Pseudomonas aeruginosa, a pathogen that can cause infections in cystic fibrosis patients and people with compromised immune systems. Upon exposure to mucin glycans, the bacteria underwent broad shifts in behaviour that rendered them less harmful to the host.
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
This microbe-disarming activity had powerful consequences on the ability of this bacterium to establish infections. Ribbeck has shown that treatment of Pseudomonas-infected burn wounds with mucins and mucin glycans reduces bacterial proliferation, indicating the therapeutic potential of these virulence-neutralising agents.


A scanning electron microscope (SEM) image of the polymer network that makes up mucins (credit: Katharina Ribbeck).
Ribbeck and other researchers are now interested in using what they have learned about mucins and glycans to develop artificial mucus, which could offer a new way to treat diseases stemming from lost or defective mucus.
Harnessing the powers of mucus could also lead to new ways to treat antibiotic-resistant infections, because it offers a complementary strategy to traditional antibiotics, Ribbeck said.
“What we find here is that nature has evolved the ability to disarm difficult microbes, instead of killing them. This would not only help limit selective pressure for developing resistance, because they are not under pressure to find ways to survive, but it should also help create and maintain a diverse microbiome,” she explained.
The study was published in Nature Microbiology.
Related topics
Antibiotics, Drug Targets, Microbiology, Research & Development, Therapeutics
Related conditions
Cystic fibrosis
Related organisations
MIT
Related people
Katharina Ribbeck